About Tempus AI, Inc. - Class A Common Stock (TEM)
Tempus AI, Inc. is a technology company focused on leveraging artificial intelligence to revolutionize the healthcare industry. The company specializes in developing data-driven solutions that provide advanced analytics and insights for precision medicine, enhancing patient care by integrating clinical and molecular data. Tempus works with healthcare providers, researchers, and pharmaceutical companies to streamline the process of matching patients with tailored treatments, ultimately aiming to improve health outcomes and accelerate advancements in medical research. By harnessing the power of machine learning and vast datasets, Tempus is at the forefront of transforming healthcare practices and fostering innovation in the medical field. Read More
West executed a sale under a pre-established Rule 10b5-1 trading plan, reducing her direct stake by 8% while retaining 34,981 shares worth roughly $1.8 million.
Bartolucci disposed of shares valued at $306,342 to cover statutory withholding obligations tied to RSU vesting, retaining direct holdings of 67,866 shares worth $3.35 million.
This non-discretionary sale to cover RSU withholding obligations reduced his direct stake, but he retains about 106,000 shares valued at $6.49 million.
Tempus AI Inc. (NASDAQ: TEM) stock jumped on Friday, August 7, 2026, following strong AI healthcare peer earnings from Doximity Inc. and a strategic lab expansion with CellCarta.
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced study results demonstrating that PRISM2, a multimodal slide-level pathology foundation model developed in collaboration with researchers from Microsoft, can perform clinically important diagnostic tasks using simple prompts and can be leveraged for a variety of downstream applications. The results were published in Nature Medicine.
Tempus AI (NASDAQ:TEM) reported second-quarter revenue growth of 22% and raised its full-year outlook, citing accelerating oncology testing volumes, expanding demand for its data and artificial intelligence offerings, and expected reimbursement benefits from newly approved diagnostic products.
Reve
Tempus AI's founder-CEO reduced an indirect stake by about 4% through a pre-scheduled trading plan, retaining roughly 6.5 million shares as the company pursues a major acquisition.
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended June 30, 2026.
AI's next winners may emerge from an overlooked part of the market. See how three software companies are turning proprietary expertise into a potentially powerful growth engine.
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of its OneOme pharmacogenomics (PGx) testing solution, delivering advanced genetic insights to optimize medication safety, dosing and toxicity risk assessment. Following its acquisition of OneOme in November 2025, Tempus has fully integrated these capabilities to expand its comprehensive precision medicine portfolio, bridging a critical gap between genomic tumor profiling and how a patient's body actually processes treatment.
Tempus AI (NASDAQ:TEM) executives said the company’s planned acquisition of Personalis is intended to strengthen its position in minimal residual disease, or MRD, testing, while expanding its biopharma data and profiling capabilities.
On a call with analysts, Tempus said it agreed to acquire all ou
Tempus, a technology company leading the adoption of AI to advance precision medicine, today highlighted results of the Articulate Pro study, published in Nature Digital Medicine, evaluating the use of AI to assist pathologists in prostate biopsy reporting.
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the second quarter ended June 30, 2026, on Thursday, July 30, 2026.
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a research collaboration with Angiosarcoma Awareness, Inc. to accelerate data-driven research in angiosarcoma, one of the rarest and most aggressive cancers. Angiosarcoma is a rare malignant tumor that starts in endothelial cells, which form the inner lining of blood vessels. It is known for its aggressive behavior, rapid progression and poor prognosis, making it a particularly challenging cancer to treat.
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced publication of successful multi-site validation of its software, which received U.S. Food and Drug Administration clearance in 2024 for predicting the one-year risk of atrial fibrillation or flutter (AF). The study, titled "Multi-Center Validation of an Artificial Intelligence-Enabled ECG Model to Predict 1-Year Risk of Atrial Fibrillation or Flutter," was recently published in Heart Rhythm.
Ambry Genetics, a leader in clinical genomic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced peer-reviewed research demonstrating the potential for variant-specific RNA testing to provide greater clarity for patients who receive a variant of uncertain significance (VUS) result from exome testing. The study, published in Genetics in Medicine Open, showcases how targeted RNA analysis using Ambry’s ExomeReveal workflow; an innovative multiomics exome sequencing approach can help resolve uncertain findings and improve diagnostic clarity.1
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference.
